J.P. Morgan Extras: Pandemic Impact on Launch, Production, Development And More
Updates From Lilly, Takeda, Amgen, Horizon, Berkeley Lights
Executive Summary
Additional views from the virtual J.P. Morgan Healthcare Conference on ways the COVID-19 pandemic has affected business practices and lessons learned for the future.
You may also be interested in...
Horizon Heralds Stellar Launch Of TED Drug Tepezza
Despite COVID-19, Horizon Therapeutics has pulled off a spectacularly successful launch of its thyroid eye disease therapy, Tepezza, thanks to pre-commercial activities that led to a high level of initial patient and prescriber awareness, and market access teams securing a decent reimbursement rate.
AZ Outlines COVID-19 Plans With Strong Q2 Update
AstraZeneca used its robust Q2 update to express hopes that Phase III data from of its COVID-19 vaccine candidate this year could provide it with a regulatory pathway. It is also entering a mAb combination into the clinic as a promising approach against COVID-19.
Showcasing Its Pandemic Response Drug Discovery, Berkeley Lights Prepares For IPO
Chief executive Eric Hobbs talks about the technology needed to accelerate antibody, cell therapy and synthetic biology, and prepare for the next pandemic.
Need a specific report? 1000+ reports available
Buy Reports